-+ 0.00%
-+ 0.00%
-+ 0.00%

THE PHASE 3 REGISTRATION STAR STUDY OF EFDAMROFUSP ALFA (IBI302) MET ITS PRIMARY ENDPOINT, MAKING IT THE FIRST SELF-DEVELOPED EXTENDED-INTERVAL TREATMENT FOR NAMD IN CHINA

路透·03/24/2026 00:00:00

登录查看新闻详情